Recent Articles
The Secrets of Getting Rich in Speculative Stocks
Over the past few days, I’ve described a unique investment technique that if performed right just once, can allow you to never worry about money again. I’m talking about venture capital-style investing. As I’ve covered, venture capitalists are the grand slam home run hitters of the investment world. They back small companies in their early stages. When it comes to evaluating early-stage companies, I use a “five factor” analytical model. In my experience, the biggest early-stage stock winners tend to have five key qualities that define their businesses.
How to Be Right Less Than 50% of the Time and Get Rich in Stocks
What would you do with an extra million dollars in cash? Retire tomorrow? Buy a new house? Buy a Ferrari? Put it in the bank and massively increase your financial freedom? Sure, it’s nice to daydream about having an extra million dollars in the bank. But I’m asking you this question because it’s a real-life situation the financial backers of early-stage companies – venture capitalists – often find themselves in. When it comes to extreme wealth creation, few endeavors can compare to being an owner of a small company that grows large.
How You Can Turn $1,000 into $1,000,000 in the Stock Market
What were you doing in 1992? The Soviet Union had just collapsed. Bill Clinton defeated George Bush in the presidential election. Roseanne, Home Improvement, and Cheers were huge TV shows. The roaring ‘90s were just getting started. And a new technology called the “Internet” was being introduced to America. Now imagine that around that time, you truly understood how this new technology would change the world. Imagine you could see the major new industries that would fan off the Internet’s creation in a dozen different directions, like spokes on a wheel.
Buy the Dip in BLUE
The action in bluebird bio (BLUE) over the last month has been manic to say the least. At first the trading was positive, as the stock rallied to a three-month high in mid-June on the back of impressive results from a Phase I/II study of a drug that treats a blood disease called beta-thalassemia. But by the end of the month BLUE had given back those gains and then some. One of the biggest culprits was Global Blood Therapeutics’ (GBT) announcement that it had received positive data from a Phase III drug trial of a treatment for sickle cell anemia. This blood disease has been a large focus of many biotechs in recent years.
Keep Your Eye on iQiyi Stock
It looks like iQiyi still has a ton of growth in its future, and this pullback is healthy. The perfect opportunity in IQ stock may be just around the corner.
Join Louis Navellier’s Market 360 — FREE!
Get Louis Navellier’s take on the news and events impacting the market, plus his top stock picks.
